enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Immunoglobulin light chain - Wikipedia

    en.wikipedia.org/wiki/Immunoglobulin_light_chain

    Only one type of light chain is present in a typical antibody, thus the two light chains of an individual antibody are identical. Each light chain is composed of two tandem immunoglobulin domains: one constant (C L) domain; one variable domain (V L) that is important for binding antigen; The approximate length of a light chain protein is from ...

  3. Monoclonal antibody therapy - Wikipedia

    en.wikipedia.org/wiki/Monoclonal_antibody_therapy

    Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]

  4. Anti-immunoglobulin - Wikipedia

    en.wikipedia.org/wiki/Anti-immunoglobulin

    Anti-Lambda Light Chain Type Description; Anti-Lambda Light Chain [N10/2] This is a recombinant monoclonal antibody to the Lambda light chain. It does not cross react with Kappa light chains. N10/2 most importantly recognizes pathologies such as leukemias, plasmacytomas, and non-Hodgkin's lymphomas. [22]

  5. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Structure of a BiTE. V H: Heavy chain variable regions. V L: Light chain variable regions. Different specificity is marked with different colours and shapes. The arrows point from N-to C-terminus. Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs.

  6. Chronic lymphocytic leukemia - Wikipedia

    en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia

    In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on the entire population of the abnormal B cells. Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa- and lambda-expressing cells.

  7. Cancer patients often do better with less intensive treatment ...

    www.aol.com/news/cancer-patients-often-better...

    The research was funded by the National Institute of Cancer in France. ESOPHAGEAL CANCER. This German study looked at 438 people with a type of cancer of the esophagus that can be treated with ...

  8. Hybridoma technology - Wikipedia

    en.wikipedia.org/wiki/Hybridoma_technology

    Double staining with light chain antibodies and with T and B cell markers can indicate the neoplastic origin of a lymphoma. [11] One study has reported the isolation of a hybridoma cell line (clone 1E10), which produces a monoclonal antibody (IgM, k isotype). This monoclonal antibody shows specific immuno-cytochemical staining of nucleoli. [12]

  9. Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment

    www.aol.com/news/japans-daiichi-sankyo-gets-us...

    AML is one of the most common types of blood cancer in adults. Mutations in the FLT3 gene, which plays a role in helping white blood cells grow, can cause excess growth of these cells and lead to ...